# Medley Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medley-genomics

- Industry: Biotechnology
- Headquarters: Providence, US
- Website: www.medleygenomics.com
- Total disclosed funding: $0.3M
- Latest round: Seed (Jan 4, 2017)
- Investors on record: 1

## About

Medley Genomics provides advanced genomic solutions that enhance drug discovery and development through innovative software tools designed for analyzing genomic data and enabling efficient identification of therapeutic targets.Medley Genomics focuses on genomic solutions that support drug discovery and development. The company is headquartered in Providence, US. In January 2017, Medley Genomics raised USD 0.25 mn in Seed funding led by Slater Technology Fund. The founder's history is not publicly available.Medley Genomics specializes in advanced genomic solutions aimed at accelerating drug discovery and development. Their primary offerings include a suite of software tools and platforms designed to analyze genomic data, enabling researchers and pharmaceutical companies to identify potential therapeutic targets more efficiently. These tools are particularly beneficial in oncology and rare disease research, where understanding genetic variations is crucial for developing effective treatments. Medley Genomics serves a diverse client base, including biotechnology firms, academic institutions, and pharmaceutical companies, predominantly within North America and Europe, where there is a high demand for innovative genomic analysis solutions. The company’s products have been well-received in these markets since their release, as they provide crucial insights that enhance the precision of drug development processes.The revenue model of Medley Genomics is structured around a combination of subscription-based access to their software platforms and partnerships with research institutions and pharmaceutical companies. Clients typically engage in annual subscriptions that grant them access to advanced analytics tools and ongoing support, ensuring they can utilize the software effectively throughout their research processes. Additionally, the company may establish collaborative agreements with larger pharmaceutical firms to facilitate customized solutions based on specific research needs. Pricing plans for these subscriptions are tailored to the scale of usage and the specific services utilized by the clients, allowing for flexibility in transactions. Through these arrangements, Medley Genomics captures a steady revenue stream from both institutional clients and industry partners who rely heavily on their genomic analysis capabilities.Following their recent Seed funding round in January 2017, Medley Genomics is focused on developing new products that enhance their current offerings, although specific upcoming launches have not been disclosed. The company also aims to expand its presence in European and Asian markets by the end of 2024, capitalizing on the growing demand for genomic analysis tools. The funding from Slater Technology Fund will be utilized to support these initiatives and enhance their software platforms to meet the evolving needs of their clients.

## Funding rounds

- Seed, Jan 4, 2017, $0.3M — Slater Technology Fund

## Investors

- Slater Technology Fund (https://capitalatlas.ai/funds/slater-technology-fund) — Seed